Nurulimab (BCD-145) is an anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) human monoclonal antibody with anti-cancer activity for the study of skin and musculoskeletal diseases.
Purity:
95.50%
CAS Number:
[2168561-20-2]
Target:
Immunology/Inflammation related|||Others
* VAT and and shipping costs not included. Errors and price changes excepted